

# APPLICATIONS

## Extraction of THC-COOH and Barbiturates from Urine using Novum™ Simplified Liquid Extraction

Matthew Brusius and Daniel Spurgin  
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA



**Matt Brusius**  
Product Manager,  
Sample Preparation  
*Matt Brusius is an avid ice hockey player. He likes skating backwards and taking slapshots from the point.*



### Introduction

In this technical note we develop a Simplified Liquid Extraction (SLE) application for barbiturates and THC-COOH from a urine matrix containing  $\beta$ -glucuronidase followed by LC-MS/MS method using Kinetex<sup>®</sup> EVO C18 LC column and SCIEX API 4000<sup>™</sup> in negative mode electrospray ionization (ESI-).

### Materials

Secobarbital, Amobarbital, Phenobarbital, Butabital, Pentobarbital, Pentobarbital-D5, 11-nor-9-Carboxy- $\Delta^9$ -THC (COOH-THC) and 11-nor-9-Carboxy- $\Delta^9$ -THC-D3 (COOH-THC-D3) standards were purchased from Cerilliant<sup>®</sup> (Round Rock, TX). Campbell Beta Glucuronidase Enzyme was purchased through Campbell Science Product, 100,000 units/mL (Rockford, IL). Formic acid was purchased from Sigma-Aldrich<sup>®</sup> (St. Louis, MO). HPLC-grade acetonitrile, methanol, methyl tert-butyl ether, ethyl acetate and hexane were purchased from Honeywell<sup>™</sup> (Morris Plains, NJ).

### Experimental Conditions

For all elution solvents, the following sample pretreatment, SLE, and LC conditions were followed, with the elution solvent being the only variant.

### Sample Pretreatment

Each sample was comprised of 150  $\mu$ L of urine, 25  $\mu$ L  $\beta$ -glucuronidase with 73  $\mu$ L of 0.1M Ammonium Acetate buffer, pH 4 and 2  $\mu$ L of barbiturate standards with THC-COOH. This 250  $\mu$ L was then combined with 200  $\mu$ L of 1% formic acid in water solution.

### SLE Protocol

<b>96-Well Plate:</b>	Novum SLE MAX
<b>Part No.:</b>	8E-S138-5GA
<b>Load:</b>	Pretreated sample and pulse vacuum (~5" Hg) for 5-10 seconds or until sample has complete entered the sorbent
<b>Elute:</b>	2 x 900 $\mu$ L aliquots of 7 test solvents (see list below) followed by a short pulse 5" Hg to initiate flow. Allow the remaining solvent to flow via gravity. At the completion of the second aliquot, apply vacuum at 5" Hg for 15 seconds to complete the extraction
<b>Dry down:</b>	Evaporate eluate to dryness @ room temperature under a gentle stream of nitrogen
<b>Reconstitute:</b>	In 200 $\mu$ L of methanol/water (50:50) containing 1% NH <sub>4</sub> OH and 100 ng/mL of COOH-THC-D3 and 250 ng/mL of Pentobarbital-D5100 ng/mL

### Tested Elution Solvents

1. MTBE (Methyl Tert-Butyl Ether)
2. Ethyl Acetate
3. Hexane/Ethyl acetate (1:1)
4. Hexane/Ethyl acetate (1:3)
5. Hexane/MTBE (1:1)
6. Hexane/MTBE (1:3)
7. Hexane/Ethyl acetate (3:1)

### LC Conditions

<b>Analytical Column:</b>	Kinetex 2.6 $\mu$ m EVO C18 100Å
<b>Dimension:</b>	50 x 2.1 mm
<b>Part No.:</b>	00B-4725-AN
<b>Recommended SecurityGuard™ ULTRA Cartridge:</b>	AJO-7844
<b>Mobile Phase:</b>	A: 10 mM Ammonium bicarbonate, pH 9 B: Acetonitrile
<b>Gradient:</b>	<b>Time (min)</b> <b>B (%)</b>
	0                    5
	2                    15
	5                    20
	5.01               60
	6                    60
	6.1                 5
	7.5                 5
<b>Flow Rate:</b>	0.5 mL/min
<b>Temperature:</b>	Room temperature
<b>Injection Volume:</b>	2 $\mu$ L
<b>Instrument:</b>	Agilent <sup>®</sup> 1200 LC System
<b>Detection:</b>	MS/MS API 4000 (SCIEX), ESI+



## Results and Discussion

While all seven solvents were screened for the SLE protocol, recovery data was only generated for the two samples that were visually the cleanest after dry down and reconstitution. **Figure 1** shows the sample vat before it is extracted using Novum<sup>™</sup> SLE. **Figure 2** shows the reconstituted samples using the following extracting solvents: MTBE (Vial A), EtOAc (Vial B), Hexane/MTBE (1:3) (Vial C) and the Hexane/EtOAc (Vial D). Vials C and D appear clearer, therefore presumptively cleaner than Vials A and B. This effect becomes more apparent with dirtier and more concentrated urine samples.

**Figure 1.** Sample prior to extraction



Hexane/MTBE (1:3)

Historically, MTBE provides acceptable recoveries for these classes of compounds, but often times provides mediocre clean up. By cutting the MTBE with a 25% volume of hexane, we are able to drastically improve the cleanup of the sample while maintaining the recovery values that are shown in **Table 1**. This extracting solvent is the best choice to achieve the highest recovery.

Hexane/EtOAc (3:1)

It has been discussed in previous technical notes that using straight hexane, or any non-oxygen containing solvent by itself with Novum SLE plates does not usually produce acceptable results. The addition of an oxygen containing solvent is usually required to help solvate the sorbent in order to promote an efficient extraction. Moreover, hexane is often so non-polar that many analytes are not soluble in it, which can be good for maintaining sample cleanliness, but not for recovery. Therefore, the addition of ethyl acetate is used to reduce the solvent's hydrophobicity to allow polar compounds (i.e. barbiturates) to be extracted while also functioning as an oxygen containing modifier to further improve extraction efficiency.

Additionally, this solvent mixture dries down faster than ethyl acetate, while providing the acceptable recovery values (**Table 1**). This solvent is the best choice for those who are interested in good recovery with fast dry down. **Figure 3** shows a chromatogram for this extract using this solvent.

**Figure 2.** Extracted samples post dry down and reconstitution in 200  $\mu$ L of solvent for visual comparison. Solvents shown are: A) MTBE, B) EtOAc, C) Hexane/MTBE (1:3), D) Hexane/EtOAc (3:1).




**Table 1.** Recovery values of Barbiturates and THC-COOH for the two visually clean solvents: Hexane/MTBE (1:3) and Hexane/EtOAc (3:1).


	Hexane/ MTBE (1:3)		Hexane/ EtOAc (3:1)	
	Average Recovery	%CV (N=4)	Average Recovery	%CV (N=4)
Amobarbital	105%	8	93%	4
Pentobarbital	95%	9	87%	4
Butobarbital	98%	11	93%	7
Phenobarbital	95%	6	85%	8
Secobarbital	103%	12	88%	13
THC-COOH	89%	6	81%	12

Basic mobile phase was selected in order to provide a stronger source of ionization in negative mode. We selected Kinetex EVO C18 for stable separation at pH 9. While the THC-COOH represented here was spiked at 100 ng – and 10 ng spike of THC-COOH was also performed; unfortunately due to system limitations, the peaks for this were merely qualitative, and since they did not meet the required threshold for quantitation (10:1 signal-to-noise ratio), integration was not performed and recovery was not calculated. However, relative approximations between pre and post spike responses, coupled with the results presented herein, indicate that the method should scale to a lower concentration of THC-COOH. An example of the neat standards are shown in **Figure 4**, which illustrates the required separation of the pentobarbital and amobarbital isomers.

**Figure 3.** Representative chromatogram for analytes extracted using Hexane/EtOAc (3:1). Peaks in order of elution: Phenobarbital (1.15 min), Butabital (2.04 min), Pentobarbital (3.21 min), Amobarbital (3.48 min), Secobarbital (4.12 min), THC-COOH (6.05 min)



**Figure 4.** Representative chromatogram of neat standards of barbiturates and THC-COOH. Peaks in order of elution: Phenobarbital (1.15 min), Butabital (2.04 min), Pentobarbital (3.21 min), Amobarbital (3.48 min), Secobarbital (4.12 min), THC-COOH (6.05 min)



# APPLICATIONS

## Conclusion

In this technical note we identified the best elution solvents for the simultaneous extraction of barbiturates and THC-COOH from urine. Using Novum SLE, coupled with Hexane/MTBE extracting solvent provided a visually clean extract and good recovery for all analytes. Hexane/EtOAc provides slightly less recovery with the same visual cleanliness, but with the added benefit of fast dry down.

## Ordering Information Kinetex<sup>®</sup> LC Columns

2.6 µm Minibore Columns (mm)					SecurityGuard <sup>™</sup> ULTRA Cartridges
Phases	30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
<b>EVO C18</b>	00A-4725-AN	00B-4725-AN	00D-4725-AN	00F-4725-AN	AJ0-9298

## Novum<sup>™</sup> Simplified Liquid Extraction (SLE)

### 96-Well Plates

Part No.	Description	Unit
8E-S138-FGA	Novum SLE MINI 96-Well Plate	1/Box
8E-S138-5GA	Novum SLE MAX 96-Well Plate	1/Box

### Tubes

Part No.	Description	Unit
8B-S138-FAK	Novum SLE 1 cc tubes	100/box
8B-S138-5BJ	Novum SLE 3 cc tubes	50/box
8B-S138-JCH	Novum SLE 6 cc tubes	30/box
8B-S138-KDG	Novum SLE 12 cc tubes	20/box

### Australia

t: +61 (0)2-9428-6444  
f: +61 (0)2-9428-6445  
auinfo@phenomenex.com

### Austria

t: +43 (0)1-319-1301  
f: +43 (0)1-319-1300  
anfrage@phenomenex.com

### Belgium

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
f: +31 (0)30-2383749  
beinfo@phenomenex.com

### Canada

t: +1 (800) 543-3681  
f: +1 (310) 328-7768  
info@phenomenex.com

### China

t: +86 400-606-8099  
f: +86 (0)22 2532-1033  
phen@agela.com

### Denmark

t: +45 4824 8048  
f: +45 4810 6265  
nordicinfo@phenomenex.com

### Finland

t: +358 (0)9 4789 0063  
f: +45 4810 6265  
nordicinfo@phenomenex.com

### France

t: +33 (0)1 30 09 21 10  
f: +33 (0)1 30 09 21 11  
franceinfo@phenomenex.com

### Germany

t: +49 (0)6021-58830-0  
f: +49 (0)6021-58830-11  
anfrage@phenomenex.com

### India

t: +91 (0)40-3012 2400  
f: +91 (0)40-3012 2411  
indiainfo@phenomenex.com

### Ireland

t: +353 (0)1 247 5405  
f: +44 1625-501796  
eireinfo@phenomenex.com

### Italy

t: +39 051 6327511  
f: +39 051 6327555  
italiainfo@phenomenex.com

### Luxembourg

t: +31 (0)30-2418700  
f: +31 (0)30-2383749  
nlinfo@phenomenex.com

### Mexico

t: 01-800-844-5226  
f: 001-310-328-7768  
tecnicomx@phenomenex.com

### The Netherlands

t: +31 (0)30-2418700  
f: +31 (0)30-2383749  
nlinfo@phenomenex.com

### New Zealand

t: +64 (0)9-4780951  
f: +64 (0)9-4780952  
nzinfo@phenomenex.com

### Norway

t: +47 810 02 005  
f: +45 4810 6265  
nordicinfo@phenomenex.com

### Puerto Rico

t: +1 (800) 541-HPLC  
f: +1 (310) 328-7768  
info@phenomenex.com

### Spain

t: +34 91-413-8613  
f: +34 91-413-2290  
espinfo@phenomenex.com

### Sweden

t: +46 (0)8 611 6950  
f: +45 4810 6265  
nordicinfo@phenomenex.com

### United Kingdom

t: +44 (0)1625-501367  
f: +44 (0)1625-501796  
ukinfo@phenomenex.com

### USA

t: +1 (310) 212-0555  
f: +1 (310) 328-7768  
info@phenomenex.com

### All other countries Corporate Office USA

t: +1 (310) 212-0555  
f: +1 (310) 328-7768  
info@phenomenex.com



If Phenomenex products in this technical note do not provide at least equivalent separation as compared to other products of the same phase and dimensions, return the product with comparative data within 45 days for a FULL REFUND.

### Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

### Trademarks

Kinetex is a registered trademark, Novum and SecurityGuard are trademarks of Phenomenex. Cerilliant is a registered trademark of Cerilliant Corporation. Sigma-Aldrich is a registered trademark of Sigma-Aldrich Co. LLC. Honeywell is a trademark of Honeywell International Inc. Agilent is a registered trademark of Agilent Technologies, Inc. API 4000 is a trademark of AB SCIEX Pte. Ltd. AB SCIEX<sup>™</sup> is being used under license.

### Disclaimer

Phenomenex is in no way affiliated with Cerilliant Corporation, Sigma-Aldrich Co. LLC, Honeywell International Inc, or Agilent Technologies, Inc.

For RESEARCH USE ONLY. Not for use in diagnostic procedures.

Novum is patent pending.

© 2017 Phenomenex, Inc. All rights reserved.

## www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)